AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02515188
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
Trial: NCT02500953
Drug: ASP3325
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02500953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04488926
Drug: Standard Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (antidepressants, anticonvulsants, muscle relaxants, weak opiates, etc..) consolidated for at least 3 months
Trial: NCT04488926
Drug: Rescue Drug
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use as needed allowed
Trial: NCT00812773
Drug: GSK2190915
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational Product
Trial: NCT00653588
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40mg
Trial: NCT02715804
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for PEGPH20
Trial: NCT00205946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
Trial: NCT04506281
Drug: neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD1 antibody (Toripalimab) combined with GEMOX chemotherapy and Lenvatinib neoadjuvant treatment
Trial: NCT00626834
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo BID
Trial: NCT02550119
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01651871
Drug: S-555739 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00907504
Drug: CP-751,871
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-751,871 20mg/kg every 3 weeks
Trial: NCT03890744
Drug: ModraDoc006/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with twice daily once weekly (BIDW) ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Trial: NCT00731679
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02683707
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV peri-procedural analgesia
Trial: NCT00646425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match basiliximab
Trial: NCT00132808
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg intravenous
Trial: NCT00132808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic 0.9% normal saline
Trial: NCT03250624
Drug: CD5024 0.3% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants applied CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 milligrams per centimeter square (mg/cm\^2) once daily for 6 weeks.
Trial: NCT03250624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants applied placebo matched to CD5024 0.3% cream topically in the evening to the affected areas as a thin film corresponding to approximately 2 mg/cm\^2 once daily for 6 weeks.
Trial: NCT02218762
Drug: Placebo to Match DISKUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
Trial: NCT00585520
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00264225
Drug: Lamaline® , 3 different doses, Dafalgan codeine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01325688
Drug: PEP005 (ingenol mebutate) Gel, 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
Trial: NCT06727357
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: in according to institutional guidelines
Trial: NCT01276990
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral drinking solution
Trial: NCT00882882
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01116310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bottles containing 60 capsules.
Trial: NCT01714713
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 1, 2
Trial: NCT03721016
Drug: MT10109L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MT10109Lwill be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Trial: NCT03721016
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be injected into either the Glabellar Lines (GL), Lateral Canthal Lines (LCL), or both.
Trial: NCT03686813
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04148937
Drug: LY3475070
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00254163
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00979927
Drug: SPC3649
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 weekly doses
Trial: NCT01581060
Drug: WX-554
RxNorm normalized name: WX-554
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules of WX-554
Trial: NCT00524043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily for 6 weeks
Trial: NCT03381625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
Trial: NCT02125630
Drug: Systemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic therapy based on tumor phenotype
Trial: NCT02117401
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
Trial: NCT02232178
Drug: 2 100mg Xaracoll implants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232178
Drug: 3 100mg Xaracoll implants
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00929591
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00929591
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00929591
Drug: endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02463318
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Melatonin is used for healthy subjects and multiple sclerosis patients
Trial: NCT00929591
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00952393
Drug: Pharmacokinetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
Trial: NCT01902121
Drug: Technosphere® Insulin 10U + 20U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Insulin
Trial: NCT01902121
Drug: Technosphere® Insulin 30U
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Insulin
Trial: NCT00769912
Drug: 50% N2O- 50%O2 mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% N2O- 50%O2 mixture administration
Trial: NCT00957086
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
Trial: NCT02210260
Drug: Diamorphine
RxNorm normalized name: Diamorphine
DrugBank: Diamorphine (DB01452)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mcg
Trial: NCT02668952
Drug: 0.9% Normal Saline (0.9% Sodium Chloride) injection
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00074542
Drug: Epanova™ (Omega-3 Free Fatty Acids)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03358004
Drug: Capecitabine 500 MG
RxNorm normalized name: capecitabine 500 MG
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
Trial: NCT01224106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received Placebo SC injection Q4W.
Trial: NCT02019758
Drug: Placebo inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo inhaler - 4 puffs twice daily
Trial: NCT00446797
Drug: Non-selective NSAIDS
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective NSAIDs administered at usual (standard) doses.
Trial: NCT00446797
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
Trial: NCT00685113
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo vaginal ring inserted vaginally and replaced every 4 weeks
Trial: NCT01735240
Drug: AZD5069
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5069 15 mg (3x5 mg capsules) single administration
Trial: NCT04147416
Drug: HSK3486 0.1-0.2 /0.3 mg / kg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered with HSK3486 at a loading dose of 0.1-0.2 mg/kg via intravenous pump. Then HSK3486 shall be administered immediately at an initial maintenance dose of 0.3 mg/kg/h respectively.
Trial: NCT00319254
Drug: SKI-606 (Bosutinib)
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
Trial: NCT03635112
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken daily by mouth (orally) for up to 12 weeks in the morning before eating.
Trial: NCT02412020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01234311
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00848783
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01829867
Drug: sNN0031
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01877811
Drug: RXDX-105
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.~During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment.
Trial: NCT02527564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01773187
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02637648
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: parallel Group administration
Trial: NCT01712204
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule BID for 16 Weeks
Trial: NCT02345213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets will be orally administered once daily after breakfast
Trial: NCT01720446
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin).
Trial: NCT00064636
Drug: VELCADE TM (bortezomib) for Injection, or PS-341
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02315534
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In arm A, BBI608 will be administered at the recommended Phase 2 dose (RP2D) twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.~In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide.
Trial: NCT02452424
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLX3397 capsules, 200 mg
Trial: NCT00103740
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mg zoledronic acid in 5 mL of sterile water for infusion
Trial: NCT00103740
Drug: placebo to zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5 mL of sterile water for infusion
Trial: NCT00103740
Drug: Placebo to risedronate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsules
Trial: NCT02212080
Drug: BAY1214784
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
Trial: NCT02212080
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
Trial: NCT00103740
Drug: Calcium and vitamin D supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium and vitamin D supplements were supplied
Trial: NCT02503150
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
Trial: NCT00525005
Drug: DOS (Docetaxel, Oxaliplatin and S-1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
Trial: NCT03363165
Drug: VM202
RxNorm normalized name: Vascular Endothelial Growth Factor 2 Plasmid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to VM202 will receive calf muscle injections of VM202 to each leg with evidence of PAD. Injections of VM202 are administered by a physician in a double-blinded fashion after randomization on Day 0, Day 14, Day 28, and Day 42, for a total of four treatment days. Therefore, participants randomized to VM202 will receive 4 mgs of VM202 in each calf muscle on each treatment day. Injections are placed beginning 2 cm below the popliteal crease, and are administered in a pre-designed sequence and pattern, at a measured distance 2 cm apart.~Note: Participants who have a evidence of PAD in only one leg will only receive injections in the leg with evidence of PAD.
Trial: NCT00006133
Drug: estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02623491
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive matching placebo.
Trial: NCT01876511
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-3475 10 mg/kg every 14 days
Trial: NCT00604006
Drug: Spironolactone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablets (placed in capsules for blinding) once daily.
Trial: NCT00604006
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose in capsules for blinding) once daily
Trial: NCT02255760
Drug: MEDI3902 - Dose 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
Trial: NCT02255760
Drug: MEDI3902 - Dose 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
Trial: NCT02255760
Drug: MEDI3902 - Dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
Trial: NCT02255760
Drug: MEDI3902 - Dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
Trial: NCT00003838
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV MTX on days +1, +3, and +6 will be given
Trial: NCT00020124
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03801226
Drug: Two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized to undergo a two-hour dwell with Dianeal Low-Calcium with 4.25% Dextrose at their first or second study visit and will receive the alternate intervention at the other study visit.
Trial: NCT00973141
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
Trial: NCT00201695
Drug: Doxil®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m2 IV day 1
Trial: NCT00169156
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 D1
Trial: NCT02145182
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride
Trial: NCT00158873
Drug: fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02111148
Drug: 5ml saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the vagina will be washed with 5ml saline and vaginal wash will be collected.
Trial: NCT03172533
Drug: ethinyl estradiol 0.03mg and dienogest 2 mg (combination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: approved oral contraceptive (Germany): Maxim
Trial: NCT03172533
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00158873
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00217191
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04331054
Drug: 2: Usual practice + SYMBICORT RAPIHALER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 puffs bid during 30 days by inhalation
Trial: NCT03001128
Drug: Antiretroviral treatment pause
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral treatment pause
Trial: NCT01574651
Drug: QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
Trial: NCT01574651
Drug: Placebo to QVA149
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
Trial: NCT02134470
Drug: Testosterone supplementation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.